Search Follow us


International Stem Cell (ISCO) is an early-stage cell therapy company currently in Phase I/IIa clinical trials to treat Parkinson’s disease (PD). In addition, ISCO sells skincare and biomedical supplies to the market, generating $8m in sales and $1.7m in underlying operating profit in 2015. The commercial businesses provide a floor under ISCO’s current valuation, creating an essentially free option on the PD candidate.

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs